PL1874278T3 - Kompozycje zawierające mikronizowany tanaproget - Google Patents

Kompozycje zawierające mikronizowany tanaproget

Info

Publication number: PL1874278T3
Authority: PL; Poland
Prior art keywords: compositions; containing micronized; micronized tanaproget; hormone; benign
Prior art date: 2005-04-28

Application number

PL06824718T

Other languages

English (en)

Inventor

Arwinder Nagi

Ramarao Chatlapalli

Shamim Hasan

Rolland Carson

Mohamed Ghorab

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-28

Filing date

2006-04-26

Publication date

2009-12-31

2006-04-26 Application filed by Wyeth Corp filed Critical Wyeth Corp

2009-12-31 Publication of PL1874278T3 publication Critical patent/PL1874278T3/pl

Links

239000000203 mixture Substances 0.000 title abstract 3
PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 title abstract 2
229950001471 tanaproget Drugs 0.000 title abstract 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
201000009030 Carcinoma Diseases 0.000 abstract 1
229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
201000009273 Endometriosis Diseases 0.000 abstract 1
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
208000009956 adenocarcinoma Diseases 0.000 abstract 1
230000000740 bleeding effect Effects 0.000 abstract 1
210000000481 breast Anatomy 0.000 abstract 1
235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
210000001072 colon Anatomy 0.000 abstract 1
229960001681 croscarmellose sodium Drugs 0.000 abstract 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
210000004696 endometrium Anatomy 0.000 abstract 1
230000037406 food intake Effects 0.000 abstract 1
235000012631 food intake Nutrition 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
238000002657 hormone replacement therapy Methods 0.000 abstract 1
210000003734 kidney Anatomy 0.000 abstract 1
201000010260 leiomyoma Diseases 0.000 abstract 1
235000019359 magnesium stearate Nutrition 0.000 abstract 1
229940057948 magnesium stearate Drugs 0.000 abstract 1
230000003211 malignant effect Effects 0.000 abstract 1
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
239000008108 microcrystalline cellulose Substances 0.000 abstract 1
229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
230000002632 myometrial effect Effects 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
210000001672 ovary Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001817 pituitary effect Effects 0.000 abstract 1
201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
229940069328 povidone Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL06824718T 2005-04-28 2006-04-26 Kompozycje zawierające mikronizowany tanaproget PL1874278T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US67559905P	2005-04-28	2005-04-28
EP06824718A EP1874278B1 (en)	2005-04-28	2006-04-26	Compositions containing micronized tanaproget
PCT/US2006/016025 WO2007030153A2 (en)	2005-04-28	2006-04-26	Compositions containing micronized tanaproget

Publications (1)

Publication Number	Publication Date
PL1874278T3 true PL1874278T3 (pl)	2009-12-31

Family

ID=37836301

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06824718T PL1874278T3 (pl)	2005-04-28	2006-04-26	Kompozycje zawierające mikronizowany tanaproget

Country Status (14)

Country	Link
US (2)	US8343965B2 (pl)
EP (1)	EP1874278B1 (pl)
JP (3)	JP5149161B2 (pl)
CN (1)	CN101166521A (pl)
AT (1)	ATE434434T1 (pl)
AU (1)	AU2006287925B2 (pl)
BR (1)	BRPI0610438A2 (pl)
CA (1)	CA2603817C (pl)
DE (1)	DE602006007453D1 (pl)
DK (1)	DK1874278T3 (pl)
ES (1)	ES2327783T3 (pl)
MX (1)	MX2007013468A (pl)
PL (1)	PL1874278T3 (pl)
WO (1)	WO2007030153A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0610433A2 (pt) *	2005-04-28	2010-11-23	Wyeth Corp	forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
SI1896034T1 (sl)	2005-04-28	2010-07-30	Wyeth Llc	Mikronizirani sestavki tanaprogeta in postopki priprave le-tega
EP1877059B8 (en) *	2005-04-28	2010-05-19	Wyeth a Corporation of the State of Delaware	Micronized tanaproget and compostions containing same
WO2007030153A2 (en)	2005-04-28	2007-03-15	Wyeth	Compositions containing micronized tanaproget
CN103989687A (zh)	2005-06-09	2014-08-20	惠氏公司	含有炔雌醇的tanaproget组合物
BRPI0819571A2 (pt)	2007-12-20	2019-09-24	Teva Womenss Health Inc	"método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US8512745B2 (en) *	2008-12-08	2013-08-20	Laboratoire Hra Pharma	Ulipristal acetate tablets
JP5714600B2 (ja)	2009-12-18	2015-05-07	フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａＮｅｄｅｒｌａｎｄＨｏｌｄｉｎｇＢ．Ｖ．	共加工された錠用賦形剤混合物、その調製及び使用
EP2545922A1 (en) *	2011-07-12	2013-01-16	PregLem S.A.	Treatment of excessive menstrual bleeding associated with uterine fibroids
JP2024530727A (ja)	2021-08-25	2024-08-23	ビーエーエスエフソシエタス・ヨーロピア	直接打錠補助組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK95093D0 (da)	1993-08-20	1993-08-20	Novo Nordisk As	Farmaceutisk formulering indeholdende et hormon
ATE386729T1 (de) *	1999-05-04	2008-03-15	Wyeth Corp	Cyclothiocarbamatderivate als progesteron- rezeptormodulatoren
UA73119C2 (en)	2000-04-19	2005-06-15	American Home Products Corpoir	Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7056906B2 (en) *	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7268149B2 (en)	2002-06-25	2007-09-11	Wyeth	Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders
RU2005101638A (ru)	2002-06-25	2006-01-20	Уайт (Us)	Использование циклокарбаматных производных для лечения гормонзависимых состояний
WO2004043434A1 (en)	2002-11-14	2004-05-27	Shear/Kershman Laboratories, Inc.	Oral testosterone delivery system with improved sustained release
US8404272B2 (en) *	2003-06-26	2013-03-26	Poly-Med, Inc.	Fiber-reinforced composite rings for intravaginal controlled drug delivery
EP1756072A2 (en)	2004-04-27	2007-02-28	Wyeth	Purification of progesterone receptor modulators
CA2562160C (en)	2004-04-27	2013-05-28	Wyeth	Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
WO2006014476A1 (en)	2004-07-07	2006-02-09	Wyeth	Cyclic progestin regimens and kits
GT200500183A (es)	2004-08-09	2006-04-10		Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es)	2004-08-09	2006-04-10		Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
SI1778710T1 (sl) *	2004-08-13	2012-05-31	Wyeth Llc	Derivati tanaprogeta metaboliti in njihove uporabe
JP2008510722A (ja) *	2004-08-20	2008-04-10	ワイス	プロゲステロン受容体構造
EP1877059B8 (en)	2005-04-28	2010-05-19	Wyeth a Corporation of the State of Delaware	Micronized tanaproget and compostions containing same
WO2007030153A2 (en)	2005-04-28	2007-03-15	Wyeth	Compositions containing micronized tanaproget
JP2008539254A (ja) *	2005-04-28	2008-11-13	ワイス	タナプロゲットの精製形態
SI1896034T1 (sl)	2005-04-28	2010-07-30	Wyeth Llc	Mikronizirani sestavki tanaprogeta in postopki priprave le-tega
BRPI0610433A2 (pt)	2005-04-28	2010-11-23	Wyeth Corp	forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
CN103989687A (zh)	2005-06-09	2014-08-20	惠氏公司	含有炔雌醇的tanaproget组合物

2006
- 2006-04-26 WO PCT/US2006/016025 patent/WO2007030153A2/en not_active Ceased
- 2006-04-26 US US11/412,014 patent/US8343965B2/en not_active Expired - Fee Related
- 2006-04-26 JP JP2008509120A patent/JP5149161B2/ja not_active Expired - Fee Related
- 2006-04-26 DE DE602006007453T patent/DE602006007453D1/de not_active Expired - Lifetime
- 2006-04-26 CN CNA2006800142222A patent/CN101166521A/zh active Pending
- 2006-04-26 CA CA2603817A patent/CA2603817C/en not_active Expired - Fee Related
- 2006-04-26 ES ES06824718T patent/ES2327783T3/es not_active Expired - Lifetime
- 2006-04-26 BR BRPI0610438-0A patent/BRPI0610438A2/pt not_active IP Right Cessation
- 2006-04-26 EP EP06824718A patent/EP1874278B1/en not_active Expired - Lifetime
- 2006-04-26 PL PL06824718T patent/PL1874278T3/pl unknown
- 2006-04-26 MX MX2007013468A patent/MX2007013468A/es active IP Right Grant
- 2006-04-26 DK DK06824718T patent/DK1874278T3/da active
- 2006-04-26 AT AT06824718T patent/ATE434434T1/de not_active IP Right Cessation
- 2006-04-26 AU AU2006287925A patent/AU2006287925B2/en not_active Ceased
2012
- 2012-07-31 JP JP2012169806A patent/JP2012254999A/ja active Pending
- 2012-11-29 US US13/689,177 patent/US8791109B2/en not_active Expired - Fee Related
2014
- 2014-05-26 JP JP2014108568A patent/JP2014205683A/ja active Pending

Also Published As

Publication number	Publication date
EP1874278A2 (en)	2008-01-09
JP2014205683A (ja)	2014-10-30
MX2007013468A (es)	2008-01-21
CA2603817C (en)	2013-03-19
JP2012254999A (ja)	2012-12-27
WO2007030153A2 (en)	2007-03-15
US8343965B2 (en)	2013-01-01
EP1874278B1 (en)	2009-06-24
US20060247234A1 (en)	2006-11-02
US8791109B2 (en)	2014-07-29
CN101166521A (zh)	2008-04-23
US20130142838A1 (en)	2013-06-06
ATE434434T1 (de)	2009-07-15
DE602006007453D1 (de)	2009-08-06
ES2327783T3 (es)	2009-11-03
BRPI0610438A2 (pt)	2012-10-23
JP5149161B2 (ja)	2013-02-20
JP2008539264A (ja)	2008-11-13
DK1874278T3 (da)	2009-09-28
WO2007030153A3 (en)	2007-08-09
AU2006287925B2 (en)	2012-03-01
AU2006287925A1 (en)	2007-03-15
CA2603817A1 (en)	2007-03-15

Publication	Publication Date	Title
CY1110017T1 (el)	2015-01-14	Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
EP1896034B8 (en)	2010-05-19	Micronized tanaproget compositions and methods of preparing the same
TW200716621A (en)	2007-05-01	Polymorph form II of tanaproget
PL1874278T3 (pl)	2009-12-31	Kompozycje zawierające mikronizowany tanaproget
JP2005511491A5 (pl)	2007-05-24
PH12012501131A1 (en)	2017-08-23	Neutralizing prolactin receptor antibodies and their therapeutic use
TW200731969A (en)	2007-09-01	Use of progesterone receptor modulators
AU2003255820A8 (en)	2004-03-11	Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
HRP20170002T1 (hr)	2017-02-24	Farmaceutski pripravci koji sadrže inhibitor aromataze
EA201491344A1 (ru)	2015-04-30	Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
HRP20100230T1 (hr)	2010-06-30	NOVI 2-SUPSTITUIRANI D-HOMO-ESTRA-1,3,5(10)-TRIENI KAO INHIBITORI 17ß-HIDROKSISTEROIDNE DEHIDROGENAZE TIPA 1
DE602005019905D1 (de)	2010-04-22	-modulatoren
UA83928C2 (ru)	2008-08-26	Производное пропан-1,3-диона или его соль
CN105796567A (zh)	2016-07-27	新利司他固体分散体及其药物制剂
ATE275973T1 (de)	2004-10-15	Empfängnisverhütende zusammensetzungen die progestagen und progesteronantagonisten enthalten
CY1109919T1 (el)	2014-09-10	Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης
MX2009009515A (es)	2009-09-16	Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
EA201000097A1 (ru)	2010-08-30	8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
JP2008517871A5 (pl)	2008-07-10
DOP2006000148A (es)	2007-07-15	Moduladores no esteroides de receptores de progesterona
RU2020138372A (ru)	2022-05-26	Композиция для лечения одного или нескольких заболеваний, связанных с эстрогеном
Cheng et al.	2009	Apoptosis and Endometriosis
JP2020114805A (ja)	2020-07-30	エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び／又は器質的病変の治療剤
Twum	2013	Development of Prodrugs to Deliver Super-potent Drugs to Prostate Tumours